26th AGM Approves Treasury Stock Acquisition and Interim Dividend; 27Q1 Net Profit Down 26% YoY


  • At the 26th AGM on March 26, 2026, resolutions for treasury stock acquisition and interim dividend were passed (shareholder proposals).
  • 27Q1 consolidated: Sales ₩21.50B (down 5.9% YoY), operating profit ₩763M, net profit ₩565M (down 26.2% YoY), EPS ₩66.
  • Total assets ₩79.46B, liabilities ₩24.37B, equity ₩55.10B (equity ratio 69.3%).
  • Foreign exchange loss of ₩406M occurred (USD/EUR fluctuations); foreign currency borrowings ₩1.63B.
  • R&D expenses ₩230M (1.07% of sales), 3 government projects in progress.
  • Cash and cash equivalents ₩8.74B, short-term financial instruments ₩17.77B.
  • Total borrowings ₩16.29B (current ₩11.71B, non-current ₩4.58B); collateral provided on assets.
  • Major shareholder: Lee Chan-ho 28.09%, others 71.45%.

KOSDAQ Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: GeneBioTech (086060)
  • Submission: GeneBioTech Co., Ltd.
  • Receipt: 05-14-2026